University of Groningen, Department of Pharmaceutical Technology and Biopharmacy , Antonius Deusinglaan 1, Groningen , Netherlands
Expert Opin Drug Deliv. 2015 Aug;12(8):1311-31. doi: 10.1517/17425247.2015.1003807. Epub 2015 Jan 19.
Therapeutic proteins and peptides often require parenteral administration, which compels frequent administration and patient discomfort. This ultimately decreases compliance and leads to therapy failure. Biocompatible and biodegradable polymers offer a versatile matrix for particles suitable for the parenteral delivery of these biomacromolecules, with the added possibility of long-term controlled release. During the past decade, research on polymeric microparticles and nanoparticles as delivery vehicles has intensified; nevertheless, only few products have been commercialized.
This review discusses the different production techniques for microparticles and nanoparticles suitable for peptide and protein delivery, including examples of recently developed formulations. Stability of the biomacromolecules related to these production techniques is evaluated, as it is a critical parameter to be considered during product development. Additionally, several strategies to improve stability are described in detail, providing insight and guidance for further formulation development.
In the conventionally used and thoroughly investigated emulsification method, stability of peptides and proteins is still a challenge. Emerging methods like solvent displacement, layer-by-layer polymer deposition, electrospraying and supercritical fluid technologies have the potential to improve stability of the protein and peptide. Nonetheless, these methods are still under development and they need critical evaluation to improve production efficiency before proceeding to in vivo efficacy studies. Improvement should be achieved by strengthening cooperation between academic research groups, pharmaceutical companies and regulatory authorities.
治疗性蛋白和肽类药物通常需要进行肠胃外给药,这迫使患者需要频繁给药,增加了患者的不适。这最终会降低患者的顺应性,导致治疗失败。生物相容性和可生物降解的聚合物为这些生物大分子的肠胃外给药提供了一种多功能的颗粒基质,并且具有长期控制释放的可能性。在过去的十年中,人们对聚合物微球和纳米粒作为药物传递载体的研究不断深入;然而,只有少数产品实现了商业化。
本综述讨论了适合肽类和蛋白类药物传递的不同类型的微球和纳米粒的生产技术,包括最近开发的制剂实例。评估了与这些生产技术相关的生物大分子的稳定性,因为它是产品开发过程中需要考虑的关键参数。此外,详细描述了几种提高稳定性的策略,为进一步的制剂开发提供了思路和指导。
在传统使用和深入研究的乳化方法中,肽类和蛋白类的稳定性仍然是一个挑战。新兴方法如溶剂置换、层层聚合物沉积、电喷雾和超临界流体技术有潜力提高蛋白和肽的稳定性。尽管如此,这些方法仍在开发中,在进行体内疗效研究之前,需要对它们进行严格的评估,以提高生产效率。应通过加强学术研究团体、制药公司和监管机构之间的合作来实现改进。